ARTICLE | Clinical News
CAP-1002 regulatory update
May 4, 2015 7:00 AM UTC
FDA granted Orphan Drug designation to CAP-1002 from Capricor to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The allogeneic cardiosphere-derived stem cell therapy is in Phase I/II testing to treat myocardial infarction (MI) and Phase I testing to treat advance heart failure. ...